BCM
LSTA icon

BML Capital Management’s Lisata Therapeutics LSTA Stock Holding History

BML Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,348
Closed -$136K – 18
2025
Q4 		$136K Sell
73,348
-36,493
-33% -$81.1K 0.12% 16
2025
Q3 		$288K Sell
109,841
-99,973
-48% -$251K 0.26% 18
2025
Q2 		$608K Sell
209,814
-7,039
-3% -$16.9K 0.46% 19
2025
Q1 		$510K Sell
216,853
-67,816
-24% -$184K 0.41% 20
2024
Q4 		$848K Hold
284,669
– – 0.53% 17
2024
Q3 		$854K Hold
284,669
– – 0.5% 20
2024
Q2 		$988K Hold
284,669
– – 0.7% 20
2024
Q1 		$888K Buy
284,669
+14,830
+5% +$43.9K 0.59% 24
2023
Q4 		$737K Buy
269,839
+26,000
+11% +$61.1K 0.56% 26
2023
Q3 		$522K Hold
243,839
– – 0.48% 20
2023
Q2 		$902K Hold
243,839
– – 0.81% 19
2023
Q1 		$791K Hold
243,839
– – 0.68% 26
2022
Q4 		$617K Buy
+243,839
New +$894K 0.59% 21

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BML Capital Management's LSTA Position: Q1 2026 in Review

BML Capital Management sold out of Lisata Therapeutics (LSTA) in Q1 2026, closing a stake of 73,348 shares — an estimated $136K sold.

BML Capital Management first reported a position in LSTA in Q4 2022 and held it in 13 quarters. The position peaked at $988K in Q2 2024. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • BML Capital Management reported no remaining Lisata Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BML Capital Management sold 73,348 Lisata Therapeutics shares in Q1 2026, an estimated $136K.
  • BML Capital Management first reported a position in Lisata Therapeutics in Q4 2022 and held it in 13 quarters.
  • BML Capital Management's Lisata Therapeutics position peaked at $988K in Q2 2024.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.